TKT

Across TCGA pan-cancer cohorts, TKT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TKT data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TKT mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TKT expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

CCRCC, COAD, and LSCC are the cancer types where TKT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.343	0.757	<.001	55	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LSCC	OS	Median	II,III,IV	0.861	0.611	.023	2	view →
PDAC	DFS	Quartile	All	0.505	0.332	.034	2	view →
UCEC	DFS	Median	All	1.000	0.936	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TKT–CCRCC (DFS)

Open the CCRCC breakdown →